

Special Issue

Local Ablation Therapy in Liver Cancer

Message from the Guest Editor

Local ablation therapy, including radiofrequency ablation (RFA), microwave ablation (MWA), and cryoablation, has been widely used as a curative treatment option for early-stage hepatocellular carcinoma (HCC) or small metastatic colorectal cancer in the liver. Recently, MWA has been emerging in the field of local ablation therapy because it has better physical properties by providing faster and higher heat than RFA. RFA has seen continuous evolution in the recent decade. Nowadays, centripetal RFA using multiple RF electrodes, even with the no-touch technique, is widely used for better local tumor control. Cryoablation is expected to produce comparable therapeutic outcomes to thermal ablation. Notably, cryoablation has been reported to have a lower complication rate in treating HCCs close to the bile duct or intrahepatic vessels than RFA. In this special issue, recent advances in local ablation therapy, including RFA, MWA, and cryoablation of liver cancer, will be updated.

Guest Editor

Dr. Min Woo Lee

School of Medicine, Sungkyunkwan University, Suwon, Republic of Korea

Deadline for manuscript submissions

closed (31 January 2024)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/149400

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)